88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
1 citations
,
November 2025 in “Journal of the American Academy of Dermatology” March 2005 in “The Nurse Practitioner” 12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
12 citations
,
February 2010 in “Journal of The American Academy of Dermatology” A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
April 2023 in “Journal of Investigative Dermatology” PX-12 may help treat psoriasis by blocking inflammation and cell death.
3 citations
,
October 2025 in “Journal of Materials Science Materials in Medicine” Hyaluronic acid is useful in cancer treatment, wound healing, and managing diseases due to its tissue compatibility and drug delivery abilities.
2 citations
,
February 2025 in “Advanced Healthcare Materials” Perhexiline can effectively target ovarian cancer cells left after treatment.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.
19 citations
,
January 2022 in “Journal of Nanomaterials” NH-Tween-80 is a promising stable gel for treating acne.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
23 citations
,
December 2004 in “Seminars in oncology” Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
August 2016 in “PolyPublie (École Polytechnique de Montréal)” Doxorubicin causes heart damage, so early detection and monitoring are important during chemotherapy.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
1 citations
,
July 2025 in “Frontiers in Endocrinology” ApoBDs, once seen as waste, are now viewed as potential tools for disease treatment and tissue repair.
November 2022 in “CARDIOMETRY” A group has developed therapies that show promise for treating cancer and various other conditions.
4 citations
,
October 2013 in “PLoS ONE” Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
48 citations
,
June 2000 in “Japanese Journal of Cancer Research” Dimethylarsinic acid speeds up skin tumor growth in certain mice.
18 citations
,
November 2003 in “Australasian Journal of Dermatology” Hair loss in this case was caused by a tumor, not typical baldness.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
50 citations
,
May 2011 in “Journal of Ethnopharmacology” Eclipta alba extract shows potential as an anticancer agent by inhibiting cancer cell growth and promoting cell death.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
10 citations
,
September 1997 in “Molecular carcinogenesis” Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.